Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-02-02 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
股东询价转让结果报告书暨持股5%以上股东权益变动触及1%整数倍的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a shareholder's transfer of shares and changes in shareholding percentages. It includes specifics about the transfer method (inquiry transfer), share quantities, prices, involved parties, and compliance with regulatory requirements. The document focuses on the change in major shareholding and the related disclosures. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report publication announcement since it contains substantive details about the transaction itself. The document fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds (here, 1%).
2026-02-02 Chinese
中信证券股份有限公司关于恩威医药股份有限公司股东向特定机构投资者询价转让股份的核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "核查报告" (Verification Report) issued by 中信证券股份有限公司 regarding a shareholder's inquiry-based transfer of shares to specific institutional investors. It details the process, qualifications, pricing, and results of a share transfer via inquiry pricing, including compliance with relevant securities laws and exchange regulations. The document is a standalone report verifying the legality and fairness of a specific share transfer transaction, not a general financial report, earnings release, or announcement of a report. It does not contain financial statements or quarterly/yearly financial data. It is not a regulatory filing or announcement of a report publication but a detailed verification report related to a capital transaction. Therefore, it fits best under the category Audit Report / Information (AR), which includes standalone audit or verification reports related to regulatory compliance and transaction fairness.
2026-02-02 Chinese
股东询价转让定价情况提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the preliminary pricing and details of a shareholder inquiry-based transfer of shares. It includes information about the pricing, participating institutional investors, and risk warnings related to the transfer. There is no detailed financial report, audit, or management discussion. The document is short (762 characters) and serves as an announcement of a capital transaction event rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. The content aligns with updates on capital structure changes or financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-01-27 Chinese
中信证券股份有限公司关于恩威医药股份有限公司股东向特定机构投资者询价转让股份相关资格的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion issued by CITIC Securities regarding the qualifications of a shareholder of Enwei Pharmaceutical Co., Ltd. for a specific institutional investor inquiry-based transfer of shares. It references regulatory guidelines and compliance checks related to share transfer qualifications, shareholder status, and adherence to stock exchange rules. The document does not contain financial statements, earnings data, or management discussion of financial results. It is a formal regulatory compliance and qualification verification report related to a capital transaction (share transfer). This fits best under Capital/Financing Update (CAP) as it concerns a share transfer and related regulatory compliance verification.
2026-01-26 Chinese
股东询价转让计划书
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a shareholder's plan to transfer shares through an inquiry-based transfer before the company's initial public offering. It details the shareholder's identity, share quantities, transfer conditions, pricing principles, and risk disclosures. The content focuses on a capital transaction involving share transfer by a major shareholder, not on financial results, management changes, or regulatory filings. The document length is about 3,066 characters, which is sufficient for a detailed announcement but not a full financial report. The key focus is on the transfer of shares and related capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-01-26 Chinese
恩威医药股份有限公司2025年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2025年度业绩预告' which translates to '2025 Annual Performance Forecast'. It provides estimated net profit figures for the full fiscal year 2025 and explains that these are preliminary estimates not audited yet. It explicitly states that detailed financial data will be disclosed in the 2025 Annual Report. The document is an announcement of expected financial results (performance forecast) rather than the actual financial report itself. The length is short (861 characters) and it serves as a notice to investors about expected earnings, which aligns with an Earnings Release (ER) rather than a full Annual Report (10-K) or Interim Report (IR). Therefore, the best classification is Earnings Release (ER).
2026-01-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.